A doctor is online now – good chance of an appointment today
Home · Blog · Mounjaro as a pill

Is Mounjaro available as a pill?

Many people search for Mounjaro as a pill because they would rather take a tablet than inject themselves. Here you get an honest overview of what is available today and what is on the way.

Adam Omari Licensed doctor and medical director, Recepta

Published 15 November 2026 · Reading time 3 min.

Short answer

No, Mounjaro is not available as a pill. Mounjaro (tirzepatide) is only given as an injection once a week. The manufacturer, Eli Lilly, has a different weight loss pill, Foundayo (orforglipron), which the European Medicines Agency (EMA) recommended for approval in the EU on 16 October 2026. If you want a pill today, Wegovy (semaglutide) is available as a daily tablet.

Is Mounjaro available as a pill or tablet?

Mounjaro is not available as a pill or tablet: Mounjaro (tirzepatide) from Eli Lilly only comes as a pen for injection once a week.

No tablet containing tirzepatide has been approved. In the SURMOUNT-1 study, the Mounjaro pen at the highest dose of 15 mg gave a weight loss of 20.9% over 72 weeks.[4]

Instead, Eli Lilly has developed a completely different pill with a different active substance. It is called Foundayo (orforglipron), is taken once a day and mimics the gut hormone GLP-1.[1]

When will Eli Lilly's weight loss pill Foundayo come to Denmark?

There is no date yet for when Eli Lilly's weight loss pill Foundayo will come to Denmark, because the pill first has to receive final approval in the EU.

Foundayo was approved in the USA on 1 April 2026. On 16 October 2026 the European Medicines Agency (EMA) recommended that Foundayo be approved in the EU for weight management and type 2 diabetes in adults. The next step is the European Commission's decision, and after that each country sets the price and reimbursement (tilskud).[5][1]

In the ATTAIN-1 study from 2025, with 3,127 adults over 72 weeks, Foundayo gave a weight loss of 7.5% with 6 mg, 8.4% with 12 mg and 11.2% with 36 mg, against 2.1% on placebo (an inactive dummy treatment). Eli Lilly itself reports 12.4% for those who stayed on the highest dose.[2][5]

What can you get today if you would rather have a pill?

If you would rather have a pill for weight loss today, a doctor can assess whether Wegovy as a daily tablet is right for you.

The Wegovy pill (semaglutide) has been on the Danish price list since 28 September 2026. In the OASIS 4 study, the highest dose of 25 mg gave a weight loss of 13.6% over 64 weeks against 2.2% on placebo. Figures from different studies cannot be compared directly.[3][6]

Today a doctor can prescribe Wegovy as a pen or pill and Mounjaro as a pen after an individual assessment. At Recepta the first doctor consultation is free.

Weight loss medication as a pill and pen: status in November 2026
MedicineFormStatus
Mounjaro (tirzepatide)Pen, once a weekCan be prescribed in Denmark. Not available as a pill.
The Wegovy pill (semaglutide)Tablet, once a dayOn the Danish price list since 28 September 2026.
Foundayo (orforglipron)Tablet, once a dayApproved in the USA. Recommended for approval in the EU on 16 October 2026. No date for Denmark.
RetatrutideInjection, once a weekStill being tested. Not approved anywhere.

Status as of November 2026.[1][6]

Read also: Wegovy or Mounjaro: which is better?

Questions and answers about Mounjaro as a pill

Is Foundayo the same as Mounjaro?
No, Foundayo is not the same as Mounjaro. Foundayo contains orforglipron and is a daily tablet, while Mounjaro contains tirzepatide and is a weekly injection. Both come from Eli Lilly.
Is retatrutide a new pill from Eli Lilly?
No, retatrutide from Eli Lilly is not a pill but a weekly injection. Retatrutide is sometimes described as the next Mounjaro, but it is still being tested and is not approved anywhere.
What side effects does the weight loss pill Foundayo have?
In the ATTAIN-1 study, the side effects of the weight loss pill Foundayo mostly came from the stomach and gut and were usually mild to moderate.

Sources

  1. European Medicines Agency (EMA): New oral GLP-1 medicine for weight management and type 2 diabetes. News, 16 October 2026. ema.europa.eu
  2. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine 2025;393(18):1796-1806. doi.org
  3. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine 2025;393(11):1077-1087. doi.org
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine 2022;387(3):205-216. doi.org
  5. Eli Lilly: Press release on the approval of Foundayo (orforglipron) in the USA, 1 April 2026.
  6. Recepta: Medication prices in Denmark (the Danish price list). recepta.dk

Would you like to know what you can get today?

A licensed Danish doctor assesses which treatment suits you. The consultation is free, and you only pay once the doctor has approved treatment.

Prescription medicine is only prescribed after the doctor's individual assessment.

This post is general information and does not replace a medical assessment. Never stop or switch medication on your own. Recepta is a doctor's clinic that treats patients with this type of medication, among others. If you have questions about a treatment you are already on, write to your doctor on My page. If you have acute symptoms, contact your own doctor, the out-of-hours doctor service (lægevagten) or call 112.